Who Paid My Doc
Marc Labbe
Sports Medicine The Woodlands, TX Medical Doctor
NPI 1306889886 CMS profile 285605
17198 St Lukes Way, Suite 600, The Woodlands, TX 77384
General payments
$237,701
Research payments
$0
Ownership & investment interest
$5,125,299
Research they led as principal investigator
$14,611
Through program year 2025, Marc Labbe of The Woodlands, TX is reported in the CMS Open Payments database as having received $237,701 across 241 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $14,611 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5,125,299 across 6 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $17,844 | 41 | |
| 2024 | General | $51,213 | 78 | |
| 2023 | General | $14,584 | 21 | |
| 2022 | General | $22,869 | 26 | |
| 2021 | General | $28,912 | 19 | |
| 2020 | General | $29,618 | 19 | |
| 2019 | General | $72,662 | 37 | |
| 2025 | Ownership | $1,730,933 | 2 | |
| 2024 | Ownership | $1,730,933 | 2 | |
| 2023 | Ownership | $1,663,433 | 2 |
Beside peers
- Marc Labbe
- Sports Medicine median
- Middle half of Sports Medicine
- National median
In program year 2025, general payments to Marc Labbe were reported at $17,844. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.
Show as a table
| Year | Marc Labbe | Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $72,662 | $1,176 | $199–$4,249 | $163 |
| 2020 | $29,618 | $708 | $96–$2,890 | $114 |
| 2021 | $28,912 | $1,213 | $152–$3,994 | $132 |
| 2022 | $22,869 | $1,230 | $159–$3,998 | $149 |
| 2023 | $14,584 | $584 | $146–$2,836 | $160 |
| 2024 | $51,213 | $628 | $163–$3,168 | $164 |
| 2025 | $17,844 | $664 | $172–$3,055 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
993
Drug cost
$15,119
Branded share of claims
15.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Celecoxib | Generic | 271 | $10,600 | |
| Lidocaine | Generic | 11 | $1,099 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 144 | $1,061 | |
| Gabapentin | Generic | 260 | $959 | |
| Doxycycline Hyclate | Generic | 41 | $494 | |
| Methylprednisolone | Generic | 55 | $343 | |
| Promethazine Hcl | Generic | 83 | $157 | |
| Cephalexin | Generic | 67 | $151 | |
| Clindamycin Hcl | Generic | 14 | $77 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 12 | $66 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 41 billing codesPaid by Medicare
$144,651
Medicare patients
309
Services billed
1,465
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 74% | |
| Ischemic heart disease | 32% | |
| Depression | 24% | |
| Diabetes | 23% | |
| Cancer | 20% | |
| Chronic kidney disease | 19% | |
| Atrial fibrillation | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 92 | 270 | $1,390 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
241 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sports Medicine in Texas
Related records
Sports Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.